Difference between revisions of "Team:Vilnius-Lithuania/Design"

Line 152: Line 152:
 
         </div>
 
         </div>
 
         <div>
 
         <div>
             Lorem ipsum dolor, sit amet consectetur adipisicing elit. Esse beatae assumenda eaque ex recusandae pariatur sunt soluta modi facere laborum exercitationem odio iure magnam obcaecati quos voluptatibus placeat, ratione harum!
+
        <div glass="<h1>ScFv Antibody</h1>"></div>
        Provident, maxime ipsum veniam, rerum facere ad vero fugit ipsa natus recusandae sit voluptatum architecto laudantium vitae necessitatibus! Nesciunt illum porro sint odio sequi reprehenderit. Sint eligendi ex impedit recusandae!
+
 
         Alias obcaecati impedit iure recusandae quas asperiores tempore sint, consectetur veniam provident iste nulla fugit velit aliquam expedita, assumenda repellat dolorem dolore! Sit quis dolorem ad pariatur repellat reiciendis officiis.
+
        <h1>Background</h1>
         Asperiores molestiae eos quo inventore recusandae quae placeat delectus, natus sint. Ullam quas culpa nobis exercitationem omnis animi velit, deleniti fugit! Sapiente aperiam sit minima nostrum, rerum quae laudantium vero?
+
      <p>
        Qui blanditiis, excepturi veritatis eaque temporibus voluptate maxime facere laborum voluptatem rerum ex a ipsum voluptatibus tempore, saepe sunt omnis nostrum sint? Voluptatum facilis omnis ea accusantium explicabo magnam architecto!
+
          <p></p>
        Repellendus incidunt doloremque, a cum voluptates esse officia quia veniam architecto. Quibusdam deserunt nulla, dolore perspiciatis accusantium ad aliquam voluptatem iste iure, quae minus ipsa voluptates, sit voluptatum consequatur tempora?
+
      </p>
        Architecto impedit in repellendus, quo dolorum sequi voluptatum omnis maxime perspiciatis aspernatur obcaecati sint iusto tenetur praesentium labore. Natus eveniet quaerat recusandae dignissimos nam sed distinctio quos fugiat aliquid eligendi.
+
             <p>scFv consists of a minimal functional antigen-binding domain of an antibody (~30 kDa) (Fig. 1) , in which the heavy variable chain (VH) and light variable chain (VL) are connected by Ser and Gly rich flexible linker. [1] In most cases scFv is expressed in bacteria, where it is produced in cytoplasm, a reducing environment, in which disulfide bonds are not able to form and protein is quickly degraded or aggregated. Although poor solubility and affinity limit scFvs’ applications, their stability can be improved by merging with other proteins. [2] When expressed in cell free system, scFv should form disulfide bonds with the help of additional molecules. Merging to a membrane protein would provide additional stability and would display scFv on liposome membrane, where its activity could be detected. These improved qualities make ScFv recombinant proteins a perfect tool to evaluate, if SynDrop system acts in an anticipated manner. Of all possible scFvs we decided to use scFv-anti vaginolysin, which binds and neutralizes toxin vaginolysin (VLY). Its main advantage is rapid (< 1 h) and cheap detection of activity by inhibition of erythrocyte lysis (Fig. 2). Looking into future applications, scFvs are also attractive targets of molecular evolution, because one round of  evolution would last less than one day thus generating a and wide range of different scFv mutants. Those displaying the highest affinity for antigens could be selected and used as drugs or drug carriers. </p>
         Molestias inventore nobis minus aspernatur recusandae asperiores excepturi ipsam voluptas quos, quae voluptatem voluptatibus vero veniam dolores fuga aliquid neque ut dolorem beatae cum temporibus tempora? Iure expedita debitis corrupti.
+
 
         Quae quam earum impedit laborum, nobis aspernatur fugit enim consequuntur provident laboriosam obcaecati doloremque ipsam quis modi quos ratione ipsum beatae? Voluptas, debitis eum! Dolorem accusantium et rem. Veniam, dicta!
+
            <p>Fig. 1</p>
         Sequi aut, eos id nemo maiores iste! Dicta cum eos, incidunt aperiam voluptate facilis vero vel deleniti inventore accusantium cupiditate saepe dolore atque quisquam voluptates aliquam amet a! Hic, consectetur.
+
 
 +
            <p><strong>Fig. 1</strong>Simplified structure of scFv Antibody</p>
 +
 
 +
            <p>Fig. 2</p>
 +
 
 +
            <p><strong>Fig. 2</strong>Scheme of scFv_antiVLY and VLY interaction. Left- scFv_antiVLY binds to VLY, erythrocytes stay intact, Right- scFv_antiVLY does not bind and VLY lyse erythrocytes.</p>
 +
         <p></p>
 +
 
 +
        <h1>Results</h1>
 +
 
 +
        scFv constructs were created BBa_K2622006"Kristina" and checked by colony PCR and DNA sequencing (link to Simas construct protocol"Kristina"). scFv synthesis was performed in a cell free system. Validation of protein expression was done by running a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), see (Fig. 3)
 +
     
 +
        <p>Fig. 3</p>
 +
 
 +
        <p><strong>Fig. 3</strong> SDS-PAGE of scFv. GFP is used as positive control, C- chaperone DnaK.</p>
 +
 
 +
         <p>Red arrows in the photo indicate scFv anti-vaginolysin (~27 kDa). As successful synthesis was confirmed, the next step was to check if protein folded correctly and was able to bind its antigen -  vaginolysin. We examined this by erythrocyte-lysis test, which was performed by comparing erythrocytes incubated with VLY (erythrocytes burst open) and erythrocytes incubated with VLY that was previously incubated with scFv anti-vaginolysin (less or no erythrocyte lysis). Results revealed that scFv binded to vaginolysin and inhibited cell lysis. Graph in (Fig. 4) demonstrates that scFv indeed attenuated the lysis of erythrocytes. These result prove scFv activity in IVTT system.</p>
 +
<p>Fig. 4</p>
 +
<p><strong>Fig. 4</strong> Percentage of erythrocyte lysis at different +/-scFv dilutions.</p>
 +
            <p>We then went one step further and constructed MstX-scFv_antiVLY (BBa_K2622038"Kristina") fusion protein, aiming to increase the stability of scFv having in mind future applications and experiments of exposing it on liposome surface. Fusion protein was expressed in E.coli cells; yellow to red arrows in (Fig. 5A) indicate MstX-scFv expression after induction with IPTG.</p>
 +
            <p>Finally, we expressed the protein in a cell free system (Fig. 5B) along with scFv in order to compare how well scFv accomplishes its function alone or binded to other protein. In this case MstX-scFv_antiVLY fusion did not show superior activity than scFv_antiVLY alone (Fig. 6). These results also reveal that scFv_antiVLY is very sensitive and loses its activity with time. Ist and IInd attempts were separated by 1-2 hours. This amount of time is enough to measure decreasing activity. This must be taken into account when performing future experiments.</p>
 +
     
 +
      <p>Fig. 5</p>
 +
      <p><strong>Fig. 5</strong>A- MstX-scFv_antiVLY expression in Escherichia coli. B- scFv_antiVLY and MstX-scFv_antiVLY expression in cell-free system.</p>
 +
     
 +
      <p>Fig. 6</p>
 +
      <p><strong>Fig. 6</strong>Fig 6. Percentage of erythrocyte lysis at different scFv/MstX-scFv dilutions.</p>
 +
     
 +
      <h1>Conclusions</h1>
 +
      <p>
 +
          <p></p>
 +
      </p>
 +
      <p>We successfully expressed scFv_antiVLY antibody and MstX-scFv_antiVLY construct in E.coli cells as well as in a cell free system. We demonstrated that our scFv anti-vaginolysin can bind to its target antigen vaginolysin and inhibit erythrocyte-lysis reaction. Based in scFv general properties in IVTT activity, we conclude that scFvs are an elegant addition to SynDrop liposome display system.</p>
 +
 
 +
      <h1>Discussion</h1>
 +
      <p>
 +
          <p>Small size of scFv makes it a widely researched antibody. It’s ability to penetrate deeply into tissues and trait to elicit low to none organism’s immune response, makes scFv the one of the best candidates for medical, diagnostic, and research applications [3]. Efficient and fast method for scFv generation is in demand. SynDrop liposome display system offers an ability to produce scFv in IVTT system and display them on membranes to facilitate rapid antigen binding. scFv on the other hand can also help us prove that our system work either cost efficiently or with extreme precision. scFv surface display is compatible with using fluorescence assisted cell sorting (FACS) to detect well functioning liposomes. [4] This would reduce amount of time needed for mutant sorting compared with enzyme-linked immunosorbent assay. Second, scFv display is compatible with the experiments described in this section. We have performed erythrocyte-lysis tests to prove the functional activity of scFv anti-vaginolysin that was synthesized in the IVTT system. Not all experiments with VLY indicated positive antibody activity. We hypothesized that proteins could have aggregated very quickly after IVTT expression and the amount of active antibody left in the solution was not enough to inhibit VLY in quantities, what would have been detectable. This hypothesis was further supported by several experiments, which revealed decreasing scFv antibody’s functional activity with time. Moreover, not every experiment was done just after IVTT reaction completed and spend few hours in +4 ˚C. Another option to test scFv, single or displayed on liposomes to gain most reliable results, is an ELISA test. It requires specific antibodies and tags (His-6x or Strep-tag) on scFv or MstX-scFv. </p>
 +
      </p>
 +
 
 +
      <h2>Refferences</h2>
 +
      <p>
 +
         <ol>
 +
        <li><p>
 +
            <ol>
 +
            <li>Monnier, P., Vigouroux, R. & Tassew, N. In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies 2, 193-208 (2013).</li>
 +
         <li>Wang, R. et al. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Frontiers in Cellular and Infection Microbiology 3, (2013).</li> 
 +
        <li>Ahmad, Z. et al. scFv Antibody: Principles and Clinical Application. Clinical and Developmental Immunology 2012, 1-15 (2012).</li>
 +
         <li>Vorauer-Uhl, K., Wagner, A., Borth, N. & Katinger, H. Determination of liposome size distribution by flow cytometry. Cytometry 39, 166 (2000).</li>
 +
        </ol>
 +
            </p></li>
 +
        </ol>
 +
        </p>
 
         </div>
 
         </div>
 
     </section>
 
     </section>
Line 232: Line 283:
 
         </p>
 
         </p>
 
         <p></p>
 
         <p></p>
         <h1>References</h1>
+
         <h2>References</h2>
 
         <p></p>
 
         <p></p>
 
         <p>
 
         <p>

Revision as of 20:04, 17 October 2018

Design and Results

RNA Thermoswitches

Cell-free, synthetic biology systems open new horizons in engineering biomolecular systems which feature complex, cell-like behaviors in the absence of living entities. Having no superior genetic control, user-controllable mechanisms to regulate gene expression are necessary to successfully operate these systems. We have created a small collection of synthetic RNA thermometers that enable temperature-dependent translation of membrane proteins, work well in cells and display great potential to be transferred to any in vitro protein synthesis system.

invert